Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D4VV
|
|||
| Former ID |
DNCL003809
|
|||
| Drug Name |
LY2874455
|
|||
| Synonyms |
LY2874455; 1254473-64-7; LY-2874455; UNII-E9M363811V; CHEMBL3828009; E9M363811V; AK186860; LY 2874455; (R,E)-2-(4-(2-(5-(1-(3,5-Dichloropyridin-4-yl)-ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol; C21H19Cl2N5O2; (R,E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol; GKJCVYLDJWTWQU-CXLRFSCWSA-N; SCHEMBL298446; SCHEMBL298445; QCR-90; GTPL8104; DTXSID20154776; MolPort-044-724-281; MolPort-023-219-117; EX-A1340; BCP04756; ZINC73069242; BDBM50189781; 2529AH; s7057; AKOS027251051
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 2 | [1], [2] | |
| Company |
Lilly
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H19Cl2N5O2
|
|||
| Canonical SMILES |
CC(C1=C(C=NC=C1Cl)Cl)OC2=CC3=C(C=C2)NN=C3C=CC4=CN(N=C4)CCO
|
|||
| InChI |
1S/C21H19Cl2N5O2/c1-13(21-17(22)10-24-11-18(21)23)30-15-3-5-20-16(8-15)19(26-27-20)4-2-14-9-25-28(12-14)6-7-29/h2-5,8-13,29H,6-7H2,1H3,(H,26,27)/b4-2+/t13-/m1/s1
|
|||
| InChIKey |
GKJCVYLDJWTWQU-CXLRFSCWSA-N
|
|||
| CAS Number |
CAS 1254473-64-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fibroblast growth factor receptor 2 (FGFR2) | Target Info | Modulator | [3] |
| KEGG Pathway | MAPK signaling pathway | |||
| Ras signaling pathway | ||||
| Rap1 signaling pathway | ||||
| Endocytosis | ||||
| PI3K-Akt signaling pathway | ||||
| Signaling pathways regulating pluripotency of stem cells | ||||
| Regulation of actin cytoskeleton | ||||
| Pathways in cancer | ||||
| Prostate cancer | ||||
| Central carbon metabolism in cancer | ||||
| NetPath Pathway | IL1 Signaling Pathway | |||
| Panther Pathway | FGF signaling pathway | |||
| Pathway Interaction Database | FGF signaling pathway | |||
| Reactome | Activated point mutants of FGFR2 | |||
| WikiPathways | Regulation of Actin Cytoskeleton | |||
| Ectoderm Differentiation | ||||
| Hair Follicle Development: Organogenesis (Part 2 of 3) | ||||
| Hair Follicle Development: Induction (Part 1 of 3) | ||||
| Cardiac Hypertrophic Response | ||||
| Signaling Pathways in Glioblastoma | ||||
| Neural Crest Differentiation | ||||
| Signaling by FGFR | ||||
| MicroRNAs in cardiomyocyte hypertrophy | ||||
| Angiogenesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8104). | |||
| REF 2 | ClinicalTrials.gov (NCT01212107) A Study of LY2874455 in Patients With Advanced Cancer. U.S. National Institutes of Health. | |||
| REF 3 | Company report (Eli Lilly) (drug: LY2874455) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.